Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | VDR | P11473 | 11/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718192 | 0.83 | SCN4A (0.40) | FFAR4VDRSCN4AFFAR1S1PR1 | |
| SCHEMBL4550407 | 0.83 | CSNK2A1 (0.41) | FFAR4SCN4AFFAR1S1PR1P2RX3 | |
| Hydrochloric Acid SCHEMBL2716625 | 0.82 | CSNK2A1 (0.43) | FFAR4SCN4AS1PR1P2RX3 | |
| SCHEMBL2713576 | 0.82 | NPC1 (0.52) | KDM4ECYP1A2 | |
| SCHEMBL2715919 | 0.81 | CYP4F2 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL2716370 | 0.80 | NPC1 (0.52) | CYP1A2 | |
| SCHEMBL16957987 | 0.79 | ALDH1A1 (0.44) | CYP4F2CYP4A11S1PR1 | |
| SCHEMBL10088505 | 0.79 | S1PR1 (0.51) | FFAR4FFAR1S1PR1 | |
| SCHEMBL27913814 | 0.78 | CCR5 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL2714554 | 0.77 | SCN4A (0.38) | CYP1A2SCN4AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| US-9944634-B2 | Pyrazolopyridine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9187475-B2 | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2914597-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2014068988-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | KDM4E 1294/4885CYP1A2 3556/4885FFAR4 4428/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | KDM4E 1168/4885CYP1A2 1397/4885FFAR4 2435/4885 |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, KCNH2, CACNA1G | KDM4E 2152/4885CYP1A2 3044/4885FFAR4 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.